Literature DB >> 6496779

A new rating scale for Alzheimer's disease.

W G Rosen, R C Mohs, K L Davis.   

Abstract

A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.

Entities:  

Mesh:

Year:  1984        PMID: 6496779     DOI: 10.1176/ajp.141.11.1356

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  953 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Authors:  Mary Sano; Rema Raman; Jennifer Emond; Ronald G Thomas; Ronald Petersen; Lon S Schneider; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

4.  To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.

Authors:  Maria G Grammatikopoulou; Dimitrios G Goulis; Konstantinos Gkiouras; Xenophon Theodoridis; Kalliopi K Gkouskou; Athanasios Evangeliou; Efthimis Dardiotis; Dimitrios P Bogdanos
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

5.  Adjuvant transcranial direct current stimulation for treating Alzheimer's disease: A case study.

Authors:  Suellen Marinho Andrade; Camila Teresa Ponce Leon de Mendonça; Thobias Cavalcanti Laurindo Pereira; Bernardino Fernandez-Calvo; Regina Coely Neves Araújo; Nelson Torro Alves
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

6.  Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

Authors:  Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-12       Impact factor: 4.105

7.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

Authors:  B J Sahakian; A M Owen; N J Morant; S A Eagger; S Boddington; L Crayton; H A Crockford; M Crooks; K Hill; R Levy
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Amnestic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake.

Authors:  Ryuji Sakakibara; Takeshi Ogata; Masayuki Haruta; Masahiko Kishi; Yohei Tsuyusaki; Akihiko Tateno; Fuyuki Tateno; Takayuki Mouri
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

Review 9.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.